

STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.27(a))-SMALL BUSINESS CONCERN

DOCKET NUMBER: 2732.1047-010

Applicant or Patentee:	Gary R. Ostroff and Gordon D. Ross (deceased)
Application or Patent No.:	
filed or Issued:	February 28, 2005
"ille:	Cancer Therapy Using Whole Glucan Particles and Antibodies
hereby state that I am	
	the small business concern identified below;
[X] an official of	the small business concern empowered to act on behalf of the concern identified below:
NAME OF SMALL B	USINESS CONCERN Biopolymer Engineering LIBUSINESS CONCERN 3388 Mike Collins Drive
ADDRESS OF SMAL	L BUSINESS CONCERN 3388 Mike Collins Drive Eagan, Minnesota 55121
ourposes of paving reduced	above identified small business concern qualifies as a small business concern as defined in 13 CFR Part 121 for fees to the United States Patent and Trademark Office. Questions related to size standards for a small business concern usiness Administration. Size Standards Staff. 409 Third Street, SW. Washington, DC 20416 or you may call
I hereby state that right the invention described in	as under contract or law have been conveyed to and remain with the small business concern identified above with regard;
	ion filed herewith with title as listed above. on identified above.
	entified above.
nvention must file separate	to above identified small business concern are not exclusive, each person, concern or organization having rights in the statements as to their status as small entities. No rights to the invention are held by any person who would not qualify as (a)(1), or by any concern which would not qualify as a small business concern under 37 CFR 1.27(a)(2), or a nonprofit 1.27(a)(3).
1) no such perso	n, concern or organization having any rights in the invention is listed below: on, concern, or organization exists. rson, concern, or organization is listed below.
	University of Louisville Research Foundation, Inc. 2301 S. Third Street Louisville, Kentucky 40208
Separate statements are	re required from each named person, concern, or organization having rights to the invention stating their status as small
l acknowledge the dur status prior to paying, or at t is no longer appropriate. (37	by to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity he time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity CFR 1.27(g)(2))
NAME OF PERSON SIGN	NG Steven I. Karel
TITLE OF PERSON IF OT	
ADDRESS OF PERSON SI	
SIGNATURE	DATE 5/27/05

EPPTDeskionN:ODMA/MHODMA/IIDSR05;IManage:552693;1

STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.27(a))-NONPROFIT ORGANIZATION

DOCKET NUMBER: 2732.1047-010

Applicant: Gary R. Ostroff and Gordon D. Ross (deceased) Application No.: 10/526,175
International Filing Date: September 4, 2003
Title: CANCER THERAPY USING WHOLE GLUCAN PARTICLES AND ANTIBODIES
I hereby state that I am an official empowered to act on behalf of the nonprofit organization identified below: NAME OF NONPROFIT ORGANIZATION University of Louisville Research Foundation, Inc. ADDRESS OF NONPROFIT ORGANIZATION 2301 S. Third Street Louisville, Kentucky 40208
TYPE OF NONPROFIT ORGANIZATION:
THE ALL PROPERTY OF A CHARLES PROPERTY OF A
[X] UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION [] TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C.501(a) and 501(c)(3)) [] NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA (NAME OF STATE
[] WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. 501(a) and 501(c)(3)) IF
LOCATED IN THE UNITED STATES OF AMERICA [
(CITATION OF STATUTE)
I hereby state that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.27(a)(3) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:
 [] the specification filed herewith with title as listed above. [X] the application identified above. [] the patent identified above.
I hereby state that the rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention. If the rights held by the nonprofit organization are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities. No rights to the invention are held by any person who would not qualify as a person under 37 CFR 1.27(a)(1) or by any concern which would not qualify as a small business concern under 37 CFR 1.27(a)(2) or a nonprofit organization under 37 CFR 1.27(a)(3).
Each additional person, concern, or organization having any rights in the invention is listed below: [] no such person, concern, or organization exists. [X] each such person, concern, or organization is listed below.
Biopolymer Engineering 3388 Mike Collins Drive Eagan, Minnesota 55121
I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.27(g)(2))
NAME OF PERSON SIGNING James R. Zanewicz, J.D.
TITLE IN ORGANIZATION OF PERSON SIGNING Director
ADDRESS OF PERSON SIGNING 201 E. Seffeson At. Swite 215, Joursville By 40202
SIGNATURE DATE 7/7/03
<i>(</i>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

[] Supplemental (37 C.F.R. §1.67)

As a named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 2 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

CANCER THERAPY USING WHOLE GLUCAN PARTICLES AND ANTIBODIES

the spec	cification of which (check one)
[]	is attached hereto.
[]	was filed on [] as United States Application Number [].
[X]	was filed on September 4, 2003 as PCT International Application No. PCT/US03/27841 and assigned United States Application No. 10/526,175.
[]	and was amended on [] (if applicable).
includin	I hereby state that I have reviewed and understand the contents of the above-identified specification, ag the claims, as amended by any amendment referred to above.
	I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby expressly authorize the filing of an International Patent Application under the Patent Cooperation Treaty which corresponds to and claims the priority of the above-identified application.

I hereby claim foreign priority benefits under 35 U.S.C. 119 or 365 of any foreign application(s) for patent or inventor's certificate, or of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

	Prior Foreign Application(s)				Priority Not Claimed		Certified Copy File YES			
(Number)	(Country)	(Day/Month/Year filed	l)	[]	[]	[]	
(Number)	(Country)	(Day/Month/Year filed	l)	[]	[]	[]	
(Number)	(Country)	(Day/Month/Year filed	1)	[]	[]	[]	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Inventor's Signature	Gary R. Ostroff	<u> </u>	
Residence: City	State	Country	Citizenship
Worcester MA	Massachusetts	USA	USA
Mailing Address (Business Street or P.O. Box	or Residential) 301 Bridle Path		
City	State	ZIP	Country
Worcester	Massachusetts	01604	USA
Full name of second joint inventor, if any	Gordon D. Ross (deceased)		
	Trunetta Jo Dockter Ross		
Legal Representative's Signature for Inventor			
Residence: City	State	Country	Citizenship
Prospect	Kentucky	USA	USA
Mailing Address (Business Street or P.O. Box	or Residential) 11739 Paramont Way		
City	State	ZIP	Country

@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;542181;1

1-00.

Customer N.º 021005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

[] Supplemental (37 C.F.R. §1.67)

As a named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 2 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

CANCER	THERAP	V USING WHO	DLE GLUCAN P	ARTICLES AND	ANTIRODIES
CANCER	THEN	T COMMENT WITH	JEE CIECEANT.	an illes and	AITIDODIES

CANC	ER THERAPY USING WHOLE GLUCAN PARTICLES AND ANTIBODIES
the spec	cification of which (check one)
[]	is attached hereto.
[]	was filed on [] as United States Application Number [].
[X]	was filed on September 4, 2003 as PCT International Application No. PCT/US03/27841 and assigned United States Application No. 10/526,175.
[]	and was amended on [] (if applicable).
includii	I hereby state that I have reviewed and understand the contents of the above-identified specification, ng the claims, as amended by any amendment referred to above.
§1.56, ifiling dapplica	I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. including for continuation-in-part applications, material information which became available between the ate of the prior application and the national or PCT international filing date of the continuation-in-part tion.

I hereby expressly authorize the filing of an International Patent Application under the Patent Cooperation Treaty which corresponds to and claims the priority of the above-identified application.

I hereby claim foreign priority benefits under 35 U.S.C. 119 or 365 of any foreign application(s) for patent or inventor's certificate, or of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

	<u>Pri</u>	ior Foreign Application(s)	Priority Not Claimed	Сору	ified Filed? NO
(Number)	(Country)	(Day/Month/Year filed)	_ []	[]	[]
(Number)	(Country)	(Day/Month/Year filed)	_ []	[]	[]
(Number)	(Country)	(Day/Month/Year filed)	_ []	[]	[]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	Gary R. Ostroff		·
Inventor's Signature			
Residence: City	State	· Country	Citizenship
Worcester	Massachusetts	· USA	USA
Mailing Address (Business Street or P.O. Box	or Residential) 301 Bridle Path		
City	. State	ZIP	Country
Worcester	Massachusetts	01604	USA
Full name of second		· · · · · · · · · · · · · · · · · · ·	
Full name of second joint inventor, if any	Gordon D. Ross (deceased)	•	
	Trunetta Jo Dockter Ross		
Legal Representative's Signature for Inventor	hunetta Do Dock	ter loss	
Danidanaa Cita	0.61	<u> </u>	01.1
Residence: City	State	Country	Citizenship
Prospect KY	Kentucky_	USA	USA
Prospect KY Mailing Address (Business	<u>Ke</u> ntucky_		T
Prospect KY Mailing Address (Business	<u>Kentucky</u> or Residential)		T

@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;542181;1

3 -- 11